Abstract | INTRODUCTION: METHODS:
Adjuvant chemotherapy consisted of eight courses (2-week administration and 1-week withdrawal) of S-1, at 80-120 mg/body per day in an outpatient setting. From July 2006 through March 2007, 30 patients were enrolled in this multi-institutional trial. RESULTS: The planned eight courses of S-1 administration were accomplished to 17 patients (56.7%; 95% confidence interval 37.4-74.5%). Two patients discontinued the treatment due to the disease recurrence, and therefore the completion rate was calculated to be 60.7%. The completion rate in patients younger than 70 years old was 78.6% while it was 42.9% in those of 70 years old or older. In seven patients including five elderly patients (> or =70 years old), S-1 administration was discontinued due to subjective symptoms, such as anorexia, during the early courses. The rate of patients with mild renal impairment (60< or = creatinine clearance<80 ml/min) tended to be higher in the elderly patients than that in the younger patients. Although grade 3 neutropenia (6.7%), anemia (6.7%), thrombocytopenia (3.3%) and digestive hemorrhage (3.3%) were observed, no grade 4 adverse events occurred. CONCLUSION: Postoperative long-term administration of S-1 seems feasible as adjuvant chemotherapy for NSCLC, with few adverse events except for the early development of anorexia, especially in the elderly patients.
|
Authors | Tokujiro Yano, Koji Yamazaki, Riichiroh Maruyama, Shoji Tokunaga, Fumihiro Shoji, Hidefumi Higashi, Sadanori Takeo, Yukito Ichinose, Yoshihiko Maehara, Lung Oncology Group in Kyushu (LOGIK) |
Journal | Lung cancer (Amsterdam, Netherlands)
(Lung Cancer)
Vol. 67
Issue 2
Pg. 184-7
(Feb 2010)
ISSN: 1872-8332 [Electronic] Ireland |
PMID | 19409643
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Copyright | Copyright 2009 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Drug Combinations
- S 1 (combination)
- Tegafur
- Oxonic Acid
|
Topics |
- Aged
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Chemotherapy, Adjuvant
- Combined Modality Therapy
- Drug Combinations
- Feasibility Studies
- Female
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Neoplasm Staging
- Oxonic Acid
(therapeutic use)
- Tegafur
(therapeutic use)
|